Gasser, Jürg A <br/><br/>
The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.  [electronic resource] 

 -  Current opinion in pharmacology  Jun 2006 
 - 313-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1471-4892 
<br/><br/><label>Standard No.: </label>10.1016/j.coph.2006.03.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Accidental Falls--prevention & control<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--pharmacology<br/>Bone Regeneration--drug effects<br/>Bone Resorption--prevention & control<br/>Cathepsin K<br/>Cathepsins--pharmacology<br/>Denosumab<br/>Diphosphonates--pharmacology<br/>Exercise Therapy<br/>Fractures, Bone--etiology<br/>Humans<br/>Osteoporosis--complications<br/>RANK Ligand<br/>Teriparatide--pharmacology